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本实验的研究对象为 2008年 1月至 2011年 2月厦门大学附属中山医院神经
外科手术中切除的胶质瘤组织 75例，其中男性 43例，女性 32例，患者年龄 12～
76 岁，平均 38.75±3.25 岁。术后根据病理结果，所有病人胶质瘤病理级别为
Ⅰ级 8 例，Ⅱ级 24 例，Ⅲ级 26 例，Ⅳ级 17 例。其中把Ⅰ级和Ⅱ级胶质瘤合并
为低级别恶性组，把Ⅲ级和Ⅳ级级胶质瘤级合并为高级别恶性组，另取 8例脑外
























1.8例正常脑组织中 CRM1表达的阳性率为 0.0%，75例脑胶质瘤中 CRM1表
达的阳性率为 70.67%，脑胶质瘤中 CRM1表达的阳性表达率较正常脑组织高，p ＜
0.05，差异具有显著性意义；8例正常脑组织中无 EGFR的表达，75例脑胶质瘤
中 EGFR表达的阳性率为 64.0%，脑胶质瘤中 EGFR表达的阳性表达率较正常脑组
织高，p＜0.05，差异具有显著性意义。 
2.CRM1的表达随着胶质瘤病理级别的升高，CRM1蛋白的表达阳性率分别为
Ⅰ级 25.00%(2/8);Ⅱ级 58.33% (14/24 );Ⅲ级 80.77%(21/26 );Ⅳ级
94.12 %(16/17)，脑胶质瘤低度恶性组阳性率为 50.00%(16/32 )与高度恶性组
阳性率为 86.05% (37/43)差异具有显著性。EGFR的表达随着胶质瘤病理级别的
升高，EGFR蛋白的表达阳性率分别Ⅰ级 25.00%(2/8);Ⅱ级 54.17% (13/24 );Ⅲ












4.在 75脑胶质瘤组织的切片标本中，CRM1和 EGFR共同阳性表达的有 40例，
CRM1和 EGFR共同阴性表达的有 14例，正常脑组织和脑胶质瘤组织 CRM1和 EGFR
的表达显著相关，p＜0.05，差异具有统计学意义。在所有 83例正常脑组织和脑
胶质瘤组织的切片标本中，CRM1和 EGFR共同阳性表达的有 40例，CRM1和 EGFR
















































Objective: The glioma is the most common malignant tumor in the central nervous 
system, and the incidence of gliomas is significantly higher than other intracerebral 
tumors, and it is not easy to cure through surgery, and easy to recurrence with poor 
prognosis. Traditional treatment methods, including surgical resection, radiotherapy, 
chemotherapy and immune therapy, have not satisfactory therapeutic effect. The 
unsatisfactory effect can be attributed to its pathogenesis which has not yet been fully 
clarified. Since patients were diagnosised with glioma in the present treatment 
conditions, 5 years of survival rate is less than 50%. With the development of 
molecular biology and molecular genetics, the occurrence and progress of glioma 
have been understudied deeply in recent years. More and more studies have shown 
that the occurrence, development, growth and invasion of cancer are related to the 
interaction of many genes, so glioma is no exception. Recently CRM1、EGFR are the 
hotspot of current research , which is closely related to the invasion and growth of 
glioma. We investigated the expressions of CRM1 and EGFR in 8 normal brain 
tissues and 75 gliomas, and analyzed their relationships, and discussed the 
relationship between the expressions of CRM1/EGFR and degree of glioma malignant,  
patient's age, patient's sex, tumor size，different positions of tumor ,patient's 
prognosis. 
Method: The paraffin-embedded specimens of glioma were taken from department 
of neurosurgery in Affiliated Zhongshan Hospital of Xiamen University from Jan 
2008 to Feb 2011, including 43 males, 32 females, age range was 12 ages to 76 ages, 
the average age is 38.75±3.25 years old. According to the standard pathological 
grades for glioma, pathological grading was classified as follows: gradeⅠ8 cases, 
grade Ⅱ24 cases, grade Ⅲ 26 cases, gradeⅣ17 cases. We combined gradeⅠand 
grade Ⅱ to low grade  glioma (LGG), and grade Ⅲ and grade Ⅳ to  high  grade 
glioma(HGG), and another 8 cases of traumatic brain injury patients with normal 
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in the normal，the LGG and the HGG by imunohistochemical Streptavidin-peroxidase 
(S-P) technique. We used respectivelyχ2 test and Fisher exact probability method to 
calculate the difference between the normal brain tissue and glioma，then  used 
correlation analysis of paired data to analyze the relevance of CRM1 and EGFR. At 
the same time, we analyzed the relationship between the expressions of CRM1/EGFR 
and degree of glioma malignant,  patient's age, patient's sex, tumor size，different 
positions of tumor ,patient's prognosis in brain glioma. 
Results: 1. The positive expression rate of CRM1 was a 0.0% positive rate in 8 cases 
of normal brain tissue. The expression of CRM1 was detected in 75 gliomas with a 
70.67% positive rate. The expression rate of CRM1 in glioma was higher than the 
normal brain tissues with the significant statistical significance (p<0.05); The positive 
expression rate of EGFR was a 0.0% positive rate in 8 cases of normal brain tissue. 
The expression of EGFR was detected in 75 gliomas with a 64.0% positive rate. The 
expression rate of EGFR in gliomas was higher than the normal brain tissues with the 
significant statistical significance (p<0.05). 
2.As the rise of the pathological level of glioma，the positive expression percentage of 
CRM1 were respectively gradeⅠ25.00% (2/8), gradeⅡ58.33 % (14/24 ), gradeⅢ
80.77%(21/26 ) , gradeⅣ94.12 %(16/17)；The positive of low-grade malignant of 
glioma was a 50.00 %( 16/32) and the highly malignant was a 86.05% (37/43). As the 
rise of the pathological level of glioma，the positive expression percentage of EGFR 
were respectively gradeⅠ 25.00% (2/8)， gradeⅡ 54.17 % (13/24 ), gradeⅢ
69.23%(18/26 ), gradeⅣ88.23%(15/17); The positive of low-grade malignant of 
glioma was a 46.88 %( 15/32) and the highly malignant was a 76.74%(33/43). We can 
know that there was significant difference between the expression of CRM1 and 
EGFR in statistics.  
3.The positive expression rate of nuclear export factor CRM1/Epidermal growth 
factor receptor EGFR between males and females in glioma patients had not 
significantly difference( p＞0.05), which difference was not statistically significant; 
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receptor EGFR between age≤40  years and age＞40 years in glioma patients had not 
significantly difference(p＞0.05), which difference was not statistically significant; 
The positive expression rate of nuclear export factor CRM1/ Epidermal growth factor 
receptor EGFR between tumor size ≤3mm and ＞3mm in glioma patients had not 
significantly difference ( p＞0.05), which difference was not statistically significant; 
The positive expression rate of nuclear export factor CRM1/ Epidermal growth factor 
receptor EGFR between survival time of less than 2 years and survival time of more 
than 2 years in glioma patients, had significantly difference with statistical 
significance (p<0.05);The positive expression rate of nuclear export factor 
CRM1/Epidermal growth factor receptor EGFR in the frontal lobe, temporal lobe, 
parietal lobe, occipital lobe, cerebellum and other parts in glioma patients had no 
significantly difference (p＞0.05), which difference was not statistically significant. 
4.  In 75 cases of glioma biopsy specimens in the organization, CRM1 and EGFR 
had a common positive expression in 40 cases, and negative expression in 22 cases, 
the expression of CRM1 and EGFR between normal brain tissue and glioma tissues  
had significantly correlation with statistical significance ,p < 0.05. In all 71 cases of 
normal brain tissue and glioma biopsy specimens in the organization, CRM1 and 
EGFR had a common positive expression in 40 cases, and negative expression in 22 
cases. The expression of CRM1 and EGFR between normal brain tissue and glioma 
tissues had significantly correlation with statistical difference significant, p < 0.05. 
Therefore, the expression of epidermal growth factor receptor EGFR with nuclear 
export factor CRM1 had statistically significant and correlation in human glioma. 
Conclusion: 1.CRM1/EGFR did not express in the normal brain tissue. But as the 
rise of the malignant degree of the glioma，the CRM1/EGFR 's expression level was 
closely related with it. There was significant differences between low-level and 
high-level gliomas, which showed that the CRM1/EGFR played an important role in 
occurrence and development of glioma. 
2.As the rise of the malignant degree of the glioma，the CRM1/EGFR's expression 
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and EGFR in the expression of human brain glioma. What's more they also played a 
very important role in occurrence and development of the glioma cells，and took 
participate in the invasive growth of glioma. So CRM1 and EGFR might become the 
effective reference index of diagnosis of the human glioma and might prove to be the 
new direction of unites the target-based research and treatment. 
3. There were no significant correlation between CRM1/EGFR's expression and sex 
and age of patients, the size of glioma, the position of glioma，but they had a 
significant correlation with survival time of patients. 2-year survival rate of patients 
with high expression of CRM1/EGFR was significantly decreased, which showed that 
nuclear export factor CRM1/epidermal growth factor receptor EGFR could be 
primitively used to judgment independent index of the patients' long-term prognostic. 




















GBM glioblastoma multiform 多形性恶性胶质瘤 






EGF Epidermal growth factor 生长因子 
SP Streptavidin Peroxides’ Conjugated Method 
链霉素抗生物素蛋白-过
氧化酶 
SPSS Statistical Product and Service Solutions 
统计产品与服务解决方
案 
VEGF vascular endothelial growth factor 血管内皮生长因子 
HIF-1 Hypoxia-inducible Factor-1 缺氧诱导因子-1 
PDGFR Platelet-derived  Growth  Factor 血小板源性生长因子 
LMB LeptomycinB 柔红霉素 
PI3K phosphoinositide-3 kinase 磷脂酰肌醇 3-激酶 
NES Nuclear export signal 出核转运信号肽 
NF-kB Nuclear Factor-kappa B 核因子-kB 
MAPK Mitogen-activated protein kinase 
有丝分裂原激活蛋白激
酶 
PBS Phosphate buffered solution 磷酸盐缓冲液 
AP-1 Activator protein 1 转录因子 AP-1 
STAT Signal transducers and activators of transcription 
信号传导及转录激活因
子 
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。包括血管内皮生长因子(Vascular Endothelial Growth Factor, VEGF)[9]、缺氧
诱导因子 -1(Hypoxia-inducible Factor-1, HIF-1)[10] 、血小板源性生长因子
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